CoChat
Sign Up
Cited by 109RNA Interference and Gene DeliveryNanoparticle-Based Drug DeliveryAdvancements in Transdermal Drug Delivery

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

Open access
Kularatne, Ruvanthi N., Crist, Rachael M., Stern, Stephan T.·2022·Pharmaceuticals
DOI 10.3390/ph15070897PMC PMC9322927
Open this paper in CoChat — free accountOpen PDF

Abstract

The earliest example of in vivo expression of exogenous mRNA is by direct intramuscular injection in mice without the aid of a delivery vehicle. The current state of the art for therapeutic nucleic acid delivery is lipid nanoparticles (LNP), which are composed of cholesterol, a helper lipid, a PEGylated lipid and an ionizable amine-containing lipid. The liver is the primary organ of LNP accumulation following intravenous administration and is also observed to varying degrees following intramuscular and subcutaneous routes. Delivery of nucleic acid to hepatocytes by LNP has therapeutic potential, but there are many disease indications that would benefit from non-hepatic LNP tissue and cell population targeting, such as cancer, and neurological, cardiovascular and infectious diseases. This review will concentrate on the current efforts to develop the next generation of tissue-targeted LNP constructs for therapeutic nucleic acids.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ph15070897

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 72

  1. [3]Eygeris Y. Gupta M. Kim J. Sahay G. Chemistry of Lipid Nanoparticles for RNA Delivery Acc. Chem. Res. 2022 55 2 12 10.1021/acs.accounts.1c00544 34850635 · DOI
  2. [4]Carrasco M.J. Alishetty S. Alameh M.G. Said H. Wright L. Paige M. Soliman O. Weissman D. Cleveland T.E.T. Grishaev A. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration Commun. Biol. 2021 4 956 10.1038/s42003-021-02441-2 34381159 PMC8358000 · DOI
  3. [5]Stern S.T. McNeil S.E. Nanotechnology safety concerns revisited Toxicol. Sci. 2008 101 4 21 10.1093/toxsci/kfm169 17602205 · DOI · Paper page
  4. [6]Shobaki N. Sato Y. Harashima H. Mixing lipids to manipulate the ionization status of lipid nanoparticles for specific tissue targeting Int. J. Nanomed. 2018 13 8395 8410 10.2147/IJN.S188016 PMC6294068 30587967 · DOI
  5. [7]Li Q. Chan C. Peterson N. Hanna R.N. Alfaro A. Allen K.L. Wu H. Dall’Acqua W.F. Borrok M.J. Santos J.L. Engineering Caveolae-Targeted Lipid Nanoparticles To Deliver mRNA to the Lungs ACS Chem. Biol. 2020 15 830 836 10.1021/acschembio.0c00003 32155049 · DOI
  6. [8]Kedmi R. Veiga N. Ramishetti S. Goldsmith M. Rosenblum D. Dammes N. Hazan-Halevy I. Nahary L. Leviatan-Ben-Arye S. Harlev M. A modular platform for targeted RNAi therapeutics Nat. Nanotechnol. 2018 13 214 219 10.1038/s41565-017-0043-5 29379205 · DOI · Paper page
  7. [9]Ramishetti S. Kedmi R. Goldsmith M. Leonard F. Sprague A.G. Godin B. Gozin M. Cullis P.R. Dykxhoorn D.M. Peer D. Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles ACS Nano 2015 9 6706 6716 10.1021/acsnano.5b02796 26042619 · DOI
  8. [10]Tombacz I. Laczko D. Shahnawaz H. Muramatsu H. Natesan A. Yadegari A. Papp T.E. Alameh M.G. Shuvaev V. Mui B.L. Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs Mol. Therapy 2021 29 3293 3304 10.1016/j.ymthe.2021.06.004 PMC8571164 34091054 · DOI
  9. [11]Parhiz H. Shuvaev V.V. Pardi N. Khoshnejad M. Kiseleva R.Y. Brenner J.S. Uhler T. Tuyishime S. Mui B.L. Tam Y.K. PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake J. Control. Release 2018 291 106 115 10.1016/j.jconrel.2018.10.015 30336167 PMC6477695 · DOI · Paper page
  10. [12]Goswami R. Chatzikleanthous D. Lou G. Giusti F. Bonci A. Taccone M. Brazzoli M. Gallorini S. Ferlenghi I. Berti F. Mannosylation of LNP Results in Improved Potency for Self-Amplifying RNA (SAM) Vaccines ACS Infect. Dis. 2019 5 1546 1558 10.1021/acsinfecdis.9b00084 31290323 · DOI · Paper page
  11. [13]Kim M. Jeong M. Hur S. Cho Y. Park J. Jung H. Seo Y. Woo H.A. Nam K.T. Lee K. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver Sci Adv. 2021 7 eabf4398 10.1126/sciadv.abf4398 33637537 PMC7909888 · DOI
  12. [14]Nakamura T. Kawai M. Sato Y. Maeki M. Tokeshi M. Harashima H. The Effect of Size and Charge of Lipid Nanoparticles Prepared by Microfluidic Mixing on Their Lymph Node Transitivity and Distribution Mol. Pharm. 2020 17 944 953 10.1021/acs.molpharmaceut.9b01182 31990567 · DOI
  13. [15]Zukancic D. Suys E.J.A. Pilkington E.H. Algarni A. Al-Wassiti H. Truong N.P. The Importance of Poly(ethylene glycol) and Lipid Structure in Targeted Gene Delivery to Lymph Nodes by Lipid Nanoparticles Pharmaceutics 2020 12 1068 10.3390/pharmaceutics12111068 PMC7695259 33182382 · DOI
  14. [16]Dilliard S.A. Cheng Q. Siegwart D.J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles Proc. Natl. Acad. Sci. USA 2021 118 e2109256118 10.1073/pnas.2109256118 34933999 PMC8719871 · DOI · Paper page
  15. [17]Cheng Q. Wei T. Farbiak L. Johnson L.T. Dilliard S.A. Siegwart D.J. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing Nat. Nanotechnol. 2020 15 313 320 10.1038/s41565-020-0669-6 32251383 PMC7735425 · DOI · Paper page
  16. [19]Alvarez-Benedicto E. Farbiak L. Marquez Ramirez M. Wang X. Johnson L.T. Mian O. Guerrero E.D. Siegwart D.J. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA) Biomater. Sci. 2022 10 549 559 10.1039/D1BM01454D 34904974 PMC9113778 · DOI
  17. [20]Lee S.M. Cheng Q. Yu X. Liu S. Johnson L.T. Siegwart D.J. A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo Angew. Chem. Int. Ed. Engl. 2021 60 5848 5853 10.1002/anie.202013927 33305471 PMC8100975 · DOI
  18. [21]Kimura S. Khalil I.A. Elewa Y.H.A. Harashima H. Novel lipid combination for delivery of plasmid DNA to immune cells in the spleen J. Control. Release 2021 330 753 764 10.1016/j.jconrel.2021.01.005 33422500 · DOI
  19. [22]Algarni A. Pilkington E.H. Suys E.J.A. Al-Wassiti H. Pouton C.W. Truong N.P. In vivo delivery of plasmid DNA by lipid nanoparticles: The influence of ionizable cationic lipids on organ-selective gene expression Biomater. Sci. 2022 10 2940 2952 10.1039/D2BM00168C 35475455 · DOI
  20. [23]Milane L. Amiji M. Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: Impact on translational nanomedicine Drug Deliv. Transl. Res. 2021 11 1309 1315 10.1007/s13346-021-00911-y 33512669 PMC7845267 · DOI
  21. [26]Di J. Du Z. Wu K. Jin S. Wang X. Li T. Xu Y. Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle Size Pharm. Res. 2022 39 105 114 10.1007/s11095-022-03166-5 35080707 PMC8791091 · DOI · Paper page
  22. [27]Bahl K. Senn J.J. Yuzhakov O. Bulychev A. Brito L.A. Hassett K.J. Laska M.E. Smith M. Almarsson O. Thompson J. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses Mol. Therapy 2017 25 1316 1327 10.1016/j.ymthe.2017.03.035 PMC5475249 28457665 · DOI · Paper page
  23. [31]Gan Z. Lokugamage M.P. Hatit M.Z.C. Loughrey D. Paunovska K. Sato M. Cristian A. Dahlman J.E. Nanoparticles containing constrained phospholipids deliver mRNA to liver immune cells in vivo without targeting ligands Bioeng. Transl. Med. 2020 5 e10161 10.1002/btm2.10161 33758781 PMC7974401 · DOI
  24. [32]Desjardins M. Griffiths G. Phagocytosis: Latex leads the way Curr. Opin. Cell Biol. 2003 15 498 503 10.1016/S0955-0674(03)00083-8 12892792 · DOI
  25. [33]Basha G. Novobrantseva T.I. Rosin N. Tam Y.Y. Hafez I.M. Wong M.K. Sugo T. Ruda V.M. Qin J. Klebanov B. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells Mol. Therapy 2011 19 2186 2200 10.1038/mt.2011.190 21971424 PMC3242662 · DOI
  26. [34]Saunders N.R.M. Paolini M.S. Fenton O.S. Poul L. Devalliere J. Mpambani F. Darmon A. Bergere M. Jibault O. Germain M. A Nanoprimer To Improve the Systemic Delivery of siRNA and mRNA Nano Lett. 2020 20 4264 4269 10.1021/acs.nanolett.0c00752 32357299 · DOI
  27. [35]Jain R. Frederick J.P. Huang E.Y. Burke K.E. Mauger D.M. Andrianova E.A. Farlow S.J. Siddiqui S. Pimentel J. Cheung-Ong K. MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct Nucleic Acid Ther. 2018 28 285 296 10.1089/nat.2018.0734 30088967 PMC6157376 · DOI · Paper page
  28. [36]Magadum A. Kurian A.A. Chepurko E. Sassi Y. Hajjar R.J. Zangi L. Specific Modified mRNA Translation System Circulation 2020 142 2485 2488 10.1161/CIRCULATIONAHA.120.047211 33347328 PMC7768930 · DOI
  29. [38]Veiga N. Goldsmith M. Granot Y. Rosenblum D. Dammes N. Kedmi R. Ramishetti S. Peer D. Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes Nat. Commun. 2018 9 4493 10.1038/s41467-018-06936-1 30374059 PMC6206083 · DOI · Paper page
  30. [39]Sago C.D. Lokugamage M.P. Islam F.Z. Krupczak B.R. Sato M. Dahlman J.E. Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution J. Am. Chem. Soc. 2018 140 17095 17105 10.1021/jacs.8b08976 30394729 PMC6556374 · DOI
  31. [40]Lokugamage M.P. Sago C.D. Gan Z. Krupczak B.R. Dahlman J.E. Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands Adv. Mater. 2019 31 e1902251 10.1002/adma.201902251 31465135 PMC6819129 · DOI
  32. [42]Lokugamage M.P. Vanover D. Beyersdorf J. Hatit M.Z.C. Rotolo L. Echeverri E.S. Peck H.E. Ni H. Yoon J.K. Kim Y. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs Nat. Biomed. Eng. 2021 5 1059 1068 10.1038/s41551-021-00786-x 34616046 PMC10197923 · DOI
  33. [44]Patel S. Ryals R.C. Weller K.K. Pennesi M.E. Sahay G. Lipid nanoparticles for delivery of messenger RNA to the back of the eye J. Control. Release 2019 303 91 100 10.1016/j.jconrel.2019.04.015 30986436 PMC6579630 · DOI · Paper page
  34. [46]Liang C. Guo B. Wu H. Shao N. Li D. Liu J. Dang L. Wang C. Li H. Li S. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy Nat. Med. 2015 21 288 294 10.1038/nm.3791 25665179 PMC5508976 · DOI
  35. [47]Rosenblum D. Gutkin A. Kedmi R. Ramishetti S. Veiga N. Jacobi A.M. Schubert M.S. Friedmann-Morvinski D. Cohen Z.R. Behlke M.A. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy Sci. Adv. 2020 6 eabc9450 10.1126/sciadv.abc9450 33208369 PMC7673804 · DOI · Paper page
  36. [48]Katakowski J.A. Mukherjee G. Wilner S.E. Maier K.E. Harrison M.T. DiLorenzo T.P. Levy M. Palliser D. Delivery of siRNAs to Dendritic Cells Using DEC205-Targeted Lipid Nanoparticles to Inhibit Immune Responses Mol. Therapy 2016 24 146 155 10.1038/mt.2015.175 PMC4754549 26412590 · DOI
  37. [49]Rurik J.G. Tombacz I. Yadegari A. Mendez Fernandez P.O. Shewale S.V. Li L. Kimura T. Soliman O.Y. Papp T.E. Tam Y.K. CAR T cells produced in vivo to treat cardiac injury Science 2022 375 91 96 10.1126/science.abm0594 34990237 PMC9983611 · DOI · Paper page
  38. [50]Kranz L.M. Diken M. Haas H. Kreiter S. Loquai C. Reuter K.C. Meng M. Fritz D. Vascotto F. Hefesha H. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy Nature 2016 534 396 401 10.1038/nature18300 27281205 · DOI · Paper page
  39. [52]Vance J.E. Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system Biochim. Biophys. Acta 2010 1801 806 818 10.1016/j.bbalip.2010.02.007 20170744 · DOI
  40. [53]Guevara M.L. Persano F. Persano S. Advances in Lipid Nanoparticles for mRNA-Based Cancer Immunotherapy Front. Chem. 2020 8 589959 10.3389/fchem.2020.589959 33195094 PMC7645050 · DOI
  41. [57]Miao L. Zhang Y. Huang L. mRNA vaccine for cancer immunotherapy Mol. Cancer 2021 20 41 10.1186/s12943-021-01335-5 33632261 PMC7905014 · DOI
  42. [59]Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-enters-agreement-acuitas-therapeutics-lipid (accessed on 13 June 2022)
  43. [60]Oberli M.A. Reichmuth A.M. Dorkin J.R. Mitchell M.J. Fenton O.S. Jaklenec A. Anderson D.G. Langer R. Blankschtein D. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy Nano Lett. 2017 17 1326 1335 10.1021/acs.nanolett.6b03329 28273716 PMC5523404 · DOI · Paper page
  44. [61]Lee K. Kim S.Y. Seo Y. Kim M.H. Chang J. Lee H. Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy Biomater. Sci. 2020 8 1101 1105 10.1039/C9BM01564G 31793928 · DOI
  45. [62]Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability J. Angiogenes Res. 2010 2 14 10.1186/2040-2384-2-14 20701757 PMC2928191 · DOI
  46. [63]Nichols J.W. Bae Y.H. EPR: Evidence and fallacy J. Control. Release 2014 190 451 464 10.1016/j.jconrel.2014.03.057 24794900 · DOI · Paper page
  47. [64]Petersen G.H. Alzghari S.K. Chee W. Sankari S.S. La-Beck N.M. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin J. Control. Release 2016 232 255 264 10.1016/j.jconrel.2016.04.028 27108612 · DOI
  48. [65]Price L.S.L. Stern S.T. Deal A.M. Kabanov A.V. Zamboni W.C. A reanalysis of nanoparticle tumor delivery using classical pharmacokinetic metrics Sci. Adv. 2020 6 eaay9249 10.1126/sciadv.aay9249 32832614 PMC7439617 · DOI · Paper page
  49. [66]Wilhelm S. Tavares A.J. Dai Q. Ohta S. Audet J. Dvorak H.F. Chan W.C.W. Analysis of nanoparticle delivery to tumours Nat. Rev. Mater. 2016 1 16014 10.1038/natrevmats.2016.14 · DOI · Paper page
  50. [67]Han L. Jiang C. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies Acta Pharm. Sin. B 2021 11 2306 2325 10.1016/j.apsb.2020.11.023 34522589 PMC8424230 · DOI · Paper page
  51. [68]Zhou Q. Dong C. Fan W. Jiang H. Xiang J. Qiu N. Piao Y. Xie T. Luo Y. Li Z. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy Biomaterials 2020 240 119902 10.1016/j.biomaterials.2020.119902 32105817 · DOI
  52. [69]Cochran R. Cochran F. Phage display and molecular imaging: Expanding fields of vision in living subjects Biotechnol. Genet. Eng. Rev. 2010 27 57 94 10.1080/02648725.2010.10648145 21415893 · DOI
  53. [70]Deramchia K. Jacobin-Valat M.J. Vallet A. Bazin H. Santarelli X. Sanchez S. Dos Santos P. Franconi J.M. Claverol S. Bonetto S. In vivo phage display to identify new human antibody fragments homing to atherosclerotic endothelial and subendothelial tissues [corrected] Am. J. Pathol. 2012 180 2576 2589 10.1016/j.ajpath.2012.02.013 22521648 · DOI
  54. [71]Fang R.H. Kroll A.V. Gao W. Zhang L. Cell Membrane Coating Nanotechnology Adv. Mater. 2018 30 e1706759 10.1002/adma.201706759 29582476 PMC5984176 · DOI · Paper page
  55. [72]Rao L. Meng Q.F. Bu L.L. Cai B. Huang Q. Sun Z.J. Zhang W.F. Li A. Guo S.S. Liu W. Erythrocyte Membrane-Coated Upconversion Nanoparticles with Minimal Protein Adsorption for Enhanced Tumor Imaging ACS Appl. Mater. Interfaces 2017 9 2159 2168 10.1021/acsami.6b14450 28050902 · DOI
  56. [73]Rao L. Yu G.T. Meng Q.F. Bu L.L. Tian R. Lin L.S. Deng H.Z. Yang W.J. Zan M.H. Ding J.X. Cancer Cell Membrane-Coated Nanoparticles for Personalized Therapy in Patient-Derived Xenograft Models Adv. Funct. Mater. 2019 29 1905671 10.1002/adfm.201905671 · DOI
  57. [74]Wang D. Dong H. Li M. Cao Y. Yang F. Zhang K. Dai W. Wang C. Zhang X. Erythrocyte-Cancer Hybrid Membrane Camouflaged Hollow Copper Sulfide Nanoparticles for Prolonged Circulation Life and Homotypic-Targeting Photothermal/Chemotherapy of Melanoma ACS Nano 2018 12 5241 5252 10.1021/acsnano.7b08355 29800517 · DOI
  58. [75]Wang S. Duan Y. Zhang Q. Komarla A. Gong H. Gao W. Zhang L. Drug Targeting via Platelet Membrane-Coated Nanoparticles Small Struct. 2020 1 2000018 10.1002/sstr.202000018 33817693 PMC8011559 · DOI
  59. [76]Chen M. Chen M. He J. Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA Artif. Cells Nanomed. Biotechnol. 2019 47 1635 1641 10.1080/21691401.2019.1608219 31027450 · DOI
  60. [77]Wang Y. Ji X. Ruan M. Liu W. Song R. Dai J. Xue W. Worm-Like Biomimetic Nanoerythrocyte Carrying siRNA for Melanoma Gene Therapy Small 2018 14 e1803002 10.1002/smll.201803002 30334353 · DOI
  61. [78]Park J.H. Mohapatra A. Zhou J. Holay M. Krishnan N. Gao W. Fang R.H. Zhang L. Virus-Mimicking Cell Membrane-Coated Nanoparticles for Cytosolic Delivery of mRNA Angew. Chem. Int. Ed. Engl. 2022 61 e202113671 10.1002/anie.202113671 34694684 PMC8727555 · DOI
  62. [79]Zhuang J. Gong H. Zhou J. Zhang Q. Gao W. Fang R.H. Zhang L. Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles Sci. Adv. 2020 6 eaaz6108 10.1126/sciadv.aaz6108 32258408 PMC7101224 · DOI
  63. [80]Mahmoud K. Swidan S. El-Nabarawi M. Teaima M. Lipid based nanoparticles as a novel treatment modality for hepatocellular carcinoma: A comprehensive review on targeting and recent advances J. Nanobiotech. 2022 20 109 10.1186/s12951-022-01309-9 35248080 PMC8898455 · DOI
  64. [81]Shinn J. Kwon N. Lee S.A. Lee Y. Smart pH-responsive nanomedicines for disease therapy J. Pharm. Investig. 2022 52 427 441 10.1007/s40005-022-00573-z PMC9083479 35573320 · DOI
  65. [82]Heshmati Aghda N. Dabbaghianamiri M. Tunnell J.W. Betancourt T. Design of smart nanomedicines for effective cancer treatment Int. J. Pharm. 2022 621 121791 10.1016/j.ijpharm.2022.121791 35525473 · DOI
  66. [83]Krishnan N. Fang R.H. Zhang L. Engineering of stimuli-responsive self-assembled biomimetic nanoparticles Adv. Drug Deliv. Rev. 2021 179 114006 10.1016/j.addr.2021.114006 34655662 · DOI
  67. [84]Salzano G. Costa D.F. Torchilin V.P. siRNA Delivery by Stimuli-Sensitive Nanocarriers Curr. Pharm. Des. 2015 21 4566 4573 10.2174/138161282131151013190410 26486143 PMC4758325 · DOI
  68. [85]De Maar J.S. Suelmann B.B.M. Braat M. van Diest P.J. Vaessen H.H.B. Witkamp A.J. Linn S.C. Moonen C.T.W. van der Wall E. Deckers R. Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in de novo stage IV breast cancer patients: Study protocol of the i-GO study BMJ Open 2020 10 e040162 10.1136/bmjopen-2020-040162 PMC7692846 33243800 · DOI
  69. [86]Tak W.Y. Lin S.M. Wang Y. Zheng J. Vecchione A. Park S.Y. Chen M.H. Wong S. Xu R. Peng C.Y. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions Clin. Cancer Res. 2018 24 73 83 10.1158/1078-0432.CCR-16-2433 29018051 · DOI
  70. [87]Yang W. Lee J.C. Chen M.H. Zhang Z.Y. Bai X.M. Yin S.S. Cao K. Wang S. Wu W. Yan K. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center J. Cancer Res. Therapeutics 2019 15 773 783 10.4103/jcrt.JCRT_801_18 31436231 · DOI
  71. [88]Yingyuad P. Mevel M. Prata C. Kontogiorgis C. Thanou M. Miller A.D. Enzyme-triggered PEGylated siRNA-nanoparticles for controlled release of siRNA J. RNAi Gene Silencing 2014 10 490 499 24741375 PMC3983657
  72. [89]Zhang J. Shrivastava S. Cleveland R.O. Rabbitts T.H. Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves ACS Appl. Mater. Interfaces 2019 11 10481 10491 10.1021/acsami.8b21398 30788952 PMC6602409 · DOI

Cited by

Sorted by citations

Authors
Kularatne, R. N., Crist, R. M., & Stern, S. T.
Affiliations
  • Frederick National Laboratory for Cancer Research (US)
  • Nanotechnology Characterization Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21702, USA
ORCID
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2022-07-20
Volume
15
Issue
7
Pages
897
ISSN
1424-8247 (ISSN-L)
DOI
10.3390/ph15070897
PMC
PMC9322927
OpenAlex
W4286500740
Cited by
109
References
13
Citations by year
2026: 21 · 2025: 41 · 2024: 26 · 2023: 17 · 2022: 4
FWCI
2.29
Type
journal article
Language
en
Open access
Licence
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Cancer Institute, National Institutes of Health (75N91019D00024)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
Keywords
lipid nanoparticles, nucleic acid delivery, mRNA therapeutics, liver targeting, intramuscular injection, helper lipids, ionizable lipids, PEGylated lipids, cancer gene therapy, neurological disorders, cardiovascular disease, infectious diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review